Home - Seven and Eight Biopharmaceuticals Inc

Redefining Cancer Research & Treatment

Seven and Eight Biopharmaceuticals Inc. is an experienced biopharmaceutical company committed to discovering and developing new and innovative immunotherapies. Researchers and Clinicians at Seven and Eight Biopharma are using advanced techniques to develop novel therapies to activate the immune system against cancer. Ongoing clinical trials are studying these novel therapies in patients with cancer.

Clinical Stage Biotech

Our lead therapy BDB001, a TLR7/8 agonist, is currently being evaluated as a monotherapy and in combination therapy with anti-PD-1 and anti-PD-L1 in patients with solid tumors.

From Concept to IND

Our immuno oncology team is conducting extensive pre-clinical research to bring novel immunotherapies from the bench to the bedside.

Experienced Leadership

The leadership team at Seven & Eight have extensive experience
in drug development, conduct of clinical trials, fundraising, and product commercialization.

Innovation

The key to effective immunotherapy treatments is to utilize existing knowledge while investigating new possibilities. Our research is leading us to novel and innovative solutions.

Leadership

We are leaders in advanced biotechnology research, discoveries and drug development.

Partnerships

Clinical partnership with Merck (MSD) and Roche (Genentech). Solid funding from experienced investors sharing a vision for cancer treatments.

Our Mission

Seven and Eight Biopharma is a clinical stage company dedicated to developing medicines that help cancer patients.
We devote our expertise and resources to explore and enhance the science of immunotherapy.

In The Press

Seven and Eight Biopharmaceuticals Inc. Announces Clinical Collaboration

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight Biopharmaceuticals Inc. today announced that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven and Eight’s BDB001,

Seven and Eight BioPharmaceuticals, Inc. Announces Clinical Collaboration to Evaluate BDB001 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

EDISON, N.J.–(BUSINESS WIRE)–Seven and Eight BioPharmaceuticals Inc. announced today that it has signed a clinical research collaboration agreement with Merck (known as MSD outside the US and Canada), through

TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – December 9, 2019 – Taiwan Liposome Company, Ltd. (“TLC”) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the